TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04828720

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ozonated oil
Description: All patients in ozone group were asked to visit the clinic on a daily basis through the first week and have their allocated therapeutic medication applied to their particular palatal donor site wounds. The wounds were coated with 2 ml ozonated oil per day, with a concentration of 15 µg of ozone/ml of olive oil. Moreover, palatal wounds in control group were managed by compressing the donor site with gauze and periodontal pack was placed. Patients in ozone group used a soft stent to protect the palatal donor wound site and to retain the tested oils in the post harvested palatal wounds. Patients were instructed firmly not to shatter the stent for 1 week. The stent was removed and reseated only by the operator during the application of medications and collection of smears. One week postoperatively, the protective stents were discontinued.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ozonated oil
Description: All patients in ozone group were asked to visit the clinic on a daily basis through the first week and have their allocated therapeutic medication applied to their particular palatal donor site wounds. The wounds were coated with 2 ml ozonated oil per day, with a concentration of 15 µg of ozone/ml of olive oil. Moreover, palatal wounds in control group were managed by compressing the donor site with gauze and periodontal pack was placed. Patients in ozone group used a soft stent to protect the palatal donor wound site and to retain the tested oils in the post harvested palatal wounds. Patients were instructed firmly not to shatter the stent for 1 week. The stent was removed and reseated only by the operator during the application of medications and collection of smears. One week postoperatively, the protective stents were discontinued.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ozonated oil
Description: All patients in ozone group were asked to visit the clinic on a daily basis through the first week and have their allocated therapeutic medication applied to their particular palatal donor site wounds. The wounds were coated with 2 ml ozonated oil per day, with a concentration of 15 µg of ozone/ml of olive oil. Moreover, palatal wounds in control group were managed by compressing the donor site with gauze and periodontal pack was placed. Patients in ozone group used a soft stent to protect the palatal donor wound site and to retain the tested oils in the post harvested palatal wounds. Patients were instructed firmly not to shatter the stent for 1 week. The stent was removed and reseated only by the operator during the application of medications and collection of smears. One week postoperatively, the protective stents were discontinued.
Study: NCT02489422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Daily Survey Administration
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Skills Training
Description: The YST intervention consists of four 30 minute in-person sessions that instructs skills to enhance mindfulness and promote relaxation. Participants will also be encouraged to practice daily at home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: The AC intervention consists of four 30 minute in-person sessions of supportive conversation. In addition, the interventionist will recommend that the patients write brief diary entries daily at home.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Actigraphy Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Actigraphy Assessment
Description: Ancillary studies
Study: NCT03726398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opsumit 10 Mg Tablet
Description: Oral tablet taken once daily
Study: NCT00627575

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lamotrigine
Description: Lamotrigine tablets will be available in 25, 50, 100 and 200 mg dose strength.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: Atorvastatin will available as 40 mg tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: Atorvastatin will available as 40 mg tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phenytoin
Description: Phenytoin will available as 100 mg capsules.
Study: NCT04883723

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shotblocker
Description: Shotblocker is a small, flat, horseshoe-shaped plastic tool that can be used to reduce pain due to intramuscular injection, suitable for all age groups, without drug properties. It is used by keeping it on the skin surface during injection and has no side effects. Shotblocker has short, non-pointed blunt protrusions on one side that connect with the skin, there is a hole in the middle of the vehicle to expose the injection site. The protruding surface of the vehicle is placed in the area to be applied just before injection. The protrusions on the surface of the Shotblocker do not pierce the skin and provide a warning for the Door Control Theory, which is thought to exist regarding pain

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Pressure
Description: The patient was placed in a prone position and the appropriate left or right ventrogluteal region was determined. Pressure was applied to the determined injection area with the thumb of the active hand for 10 seconds. Immediately after the application of pressure was terminated, the injection site was cleaned with an alcohol cotton pad with circular movements of 5 cm diameter from inside to outside, and the alcohol was allowed to dry. With a single movement at a 90 ° angle, the compression area was entered quickly and the injection was performed. Manual pressure reduces pain within the framework of the gate control theory. According to the gate control theory, when pressure is applied to an area, a fiber transmits the feeling of pressure instead of pain and ultimately the pain sensation is alleviated. There are many studies in the literature that prove the effectiveness of this method.
Study: NCT02849353

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryosurgery
Description: Percutaneous ablation under CT or ultrasound guidance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Percutaneous ablation under CT or ultrasound guidance

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK immunotherapy
Description: Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
Study: NCT02772289

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchyme Stem Cells low-dose group
Description: Participants will receive transdermal one dose of 1\*10\^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous three days and then receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous next three days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchyme Stem Cells high-dose group
Description: Participants will receive transdermal one dose of 1\*10\^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
Study: NCT01024725

Intervention type: OTHER
Intervention: Follow-up
Description: Nasopharyngeal/oropharyngeal and blood samples, interviews, questionnaires, register data

Intervention type: OTHER
Intervention: Follow-up
Description: Nasopharyngeal/oropharyngeal and blood samples, interviews, questionnaires, register data
Study: NCT03964558

Intervention type: DRUG
Group type: OTHER
Intervention: [14C]-acebilustat solution
Description: Acebilustat is a novel synthetic small molecule leukotriene A4 hydrolase (LTA4H) inhibitor.
Study: NCT02772289

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
Study: NCT00746798

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChimeriVax-WN02 vaccine
Description: low dose, approximately 4 x 3log10, given one time subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChimeriVax-WN02 vaccine
Description: medium dose, approximately 4 x 4log10, given one time

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChimeriVax-WN02 vaccine
Description: high dose, approximately 4 x 5log10, given one time subcutaneously
Study: NCT02358356

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: octreotate
Description: 7.8GBq 177Lu Octreotate (Lutate) given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: octreotate
Description: 7.8GBq 177Lu Octreotate (Lutate) given intravenously (IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: oral capecitabine 750mg/m2 b.i.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: oral capecitabine 750mg/m2 b.i.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: temozolomide 75mg/m2 b.i.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: temozolomide 75mg/m2 b.i.d.
Study: NCT00201162

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy
Description: Dietary supplement of isolated soy protein containing isoflavones

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: dietary supplement casein placebo
Study: NCT00158132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol 100mg/day in 3 divided doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol 100mg/day in 3 divided doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine
Description: Amantadine 100mg three times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine
Description: Amantadine 100mg three times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills
Study: NCT01479426

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EFLA400
Description: EFLA400(960mg/day)for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo(960mg/day) for 12 weeks
Study: NCT02545543

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seqirus QIV
Description: Seqirus QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.~The subject's age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator QIV
Description: The US-licensed Comparator QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.~The subject's age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination.
Study: NCT03714269

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: measurement evaluated with an isokinetic dynamometer
Description: measurement of the maximum dorsiflexion angle in degrees evaluated on an isokinetic dynamometer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: measurement evaluated with an 2D ultrasound
Description: * simultaneous recording of force torque, joint angle and myotendinous junction displacement in 2D ultrasound during 5 passive mobilization cycles of ankle flexion-extension at very low speed~* recording of static images in 2D ultrasound representing the proximal insertion of the gastrocnemius muscle in the internal condyle of the femur, the myotendinous junction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: assessment of the level of discomfort
Description: visual analogue scale (0 = no discomfort and 10 = maximal discomfort)
Study: NCT01770444

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-dose Cardiac CT protocol
Description: A cardiac CT protocol modified for reduction of radiation exposure~1. Prospective gating~2. Range: dedicated imaging (below carina to heart base)

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional cardiac CT protocol
Description: Conventional CCTA protocol~1. Retrospective gating with tube current modulation~2. Range: dedicated imaging (below carina to heart base)
Study: NCT02081066

Intervention type: OTHER
Group type: OTHER
Intervention: cardiovascular risk factors
Study: NCT00576979

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Occurs approximately 48 hours after completion of cyclophosphamide

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Occurs approximately 48 hours after completion of cyclophosphamide
Study: NCT02970682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SFX-01
Description: Stabilised Sulforaphane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SFX-01
Description: Stabilised Sulforaphane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SFX-01
Description: Stabilised Sulforaphane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Tamoxifen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitors
Study: NCT01801345

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fatigued

Intervention type: OTHER
Group type: OTHER
Intervention: Rested
Study: NCT02303418

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Carbetocin will be given slowly iv after delivery of the baby

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin will be given slowly iv after delivery of the baby
Study: NCT00479271

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home based, flexible, stepped care intervention
Description: Home based, flexible, stepped care intervention

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Home based, flexible, stepped care intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.
Description: Home based, flexible, stepped care intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.
Study: NCT00270842

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: This intervention is a 10 week Tai Chi group exercise class designed specifically for persons with Peripheral Neuropathy, having difficulty feeling their feet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Balance
Description: This intervention is a 10 week Functional Balance group exercise class designed specifically for persons with Peripheral Neuropathy, having difficulty feeling their feet.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Education Control group
Description: This control group participated in 10 weeks of general health education classes.
Study: NCT02181270

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high intensity exercise
Description: Subjects will perform 5-10 minute warm-up (50% VO2peak). Subjects will then exercise at an exercise intensity that corresponds to 90% HRmax, for 4 minutes. This will be followed by 3 min of exercise at 55% HRmax. Four of these exercise intervals/recovery periods will be completed. The total exercise commitment will be \~45 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: continuous moderate exercise
Description: Subjects will perform a 5-10 minute warm-up at 50% VO2peak. Thereafter, the intensity of exercise will be increased to 70% VO2peak by increasing the speed and incline of the treadmill. Subjects will exercise at this intensity for 60 minutes.
Study: NCT01136187

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Access site in primary PCI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Access site in primary PCI
Study: NCT00243607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hydrotherapy according to Kneipp rules
Description: 2-5 applications of hydrotherapy according to Kneipp rules (self application) per day
Study: NCT00576979

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Occurs approximately 48 hours after completion of cyclophosphamide

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Occurs approximately 48 hours after completion of cyclophosphamide

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Occurs approximately 48 hours after completion of cyclophosphamide

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Occurs approximately 48 hours after completion of cyclophosphamide
Study: NCT02518880

Intervention type: OTHER
Group type: OTHER
Intervention: Parabolic flight

Intervention type: OTHER
Group type: OTHER
Intervention: plasma volume measurements
Study: NCT02593071

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV-F Vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Buffer Placebo
Study: NCT00539175

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: infrared light
Description: pulsed infrared light will be applied to feet, ankles and popliteal fossae of patients with diabetic neuropathy

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: infrared light; placebo
Description: patients will be exposed to the same machine used to provide pulsed infrared light, but the light emitting diodes will not be activated. All other aspects of the treatment will be the same. The patient and investigator will be blind to treatment assignment.
Study: NCT00710762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF1120

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00436501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 25 mg/m\^2 given intravenously (IV) over 1 hour (+/- 10 minutes) following VEGF Trap every 3 weeks starting cycle 1 (21 day cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 25 mg/m\^2 given intravenously (IV) over 1 hour (+/- 10 minutes) following VEGF Trap every 3 weeks starting cycle 1 (21 day cycles)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ziv-aflibercept
Description: Starting dose 2 mg/kg given IV Cycle 0. Phase I Group: Every 3 weeks beginning with Cycle 0 (Completed 03/14/2008); Phase II Group: Every 3 weeks starting cycle 1 (Opened 05/09/2008).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ziv-aflibercept
Description: Starting dose 2 mg/kg given IV Cycle 0. Phase I Group: Every 3 weeks beginning with Cycle 0 (Completed 03/14/2008); Phase II Group: Every 3 weeks starting cycle 1 (Opened 05/09/2008).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT01233518

Intervention type: DEVICE
Group type: OTHER
Intervention: FFR
Description: Fractional flow reserve measured during cardiac catheterization
Study: NCT01761032

Intervention type: DEVICE
Intervention: Tanning
Description: Participants will be placed under a tanning canopy for 4-10 minutes.

Intervention type: DEVICE
Intervention: Tanning
Description: Participants will be placed under a tanning canopy for 4-10 minutes.
Study: NCT00002952

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MART-1 antigen
Description: Melan-A peptide loaded PBMCs (sc, q3wk x 3)
Study: NCT00746798

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9%Normal Saline for Injection, given one time subcutaneously
Study: NCT00946166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: 40 mg daily in the evening for a maximum of 14 days
Study: NCT00002952

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant MAGE-3.1 antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-12
Description: rhIL-12 (4 mcg, sc, days 1, 3 and 5 of every 3 wk cycle)
Study: NCT03415776

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Description: Renal replacement therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Description: Renal replacement therapy
Study: NCT00954096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transdermal nicotine patch (7mg)
Description: A 7mg transdermal nicotine patch will be applied to the subject's arm for an 8 hour period.
Study: NCT01892384

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: BI 409306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: BI 409306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: BI 409306
Study: NCT04686058

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol 10 MG/ML Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol 10 MG/ML Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidine Hydrochloride 50 Mg/mL Solution for Injection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: target controlled infusion pump

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: patient-controlled sedation pump